# Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects

> **NCT06714955** · PHASE1 · COMPLETED · sponsor: **BrightGene Bio-Medical Technology Co., Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Non-diabetic Overweight or Obese

## Interventions

- **DRUG:** Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
- **DRUG:** Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.
- **DRUG:** Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.

## Key facts

- **NCT ID:** NCT06714955
- **Lead sponsor:** BrightGene Bio-Medical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-21
- **Primary completion:** 2025-01-21
- **Final completion:** 2025-03-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06714955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06714955, "Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06714955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*